BC Week In Review | Apr 12, 2019
Company News

Ascentage, Junshi to evaluate APG-1387-toripalimab combo for cancer

Ascentage and Junshi partnered to conduct clinical trials in China evaluating APG-1387 in combination with Tuoyi toripalimab to treat solid tumors and hematological cancers. Ascentage Pharma Group Corp. Ltd. (Suzhou, China) declined to disclose details,...
BC Week In Review | Jan 18, 2019
Company News

MD Anderson collaborating with Ascentage, Nanobiotix on clinical testing of cancer assets

The University of Texas MD Anderson Cancer Center unveiled two new partnerships with China's Ascentage Pharma Group International (Suzhou, China) and France's Nanobiotix S.A. (Euronext:NANO) for clinical testing of their respective cancer assets. MD Anderson's...
BC Extra | Jan 7, 2019
Politics & Policy

Bipartisan bill to streamline U.S. response to foreign theft of IP may hasten clarity on biotech impact

As the biopharma industry awaits guidance from the government on the scope and potential impact of proposed technology export controls, a new congressional bill could help speed the process. Members of the Senate Select Committee...
BC Week In Review | Jun 1, 2018
Clinical News

Ascentage reports Phase I safety data for IAP inhibitor in solid tumors

Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) said IV APG-1387 once every week for three out of four weeks in each 28-day cycle was well tolerated with manageable adverse events in 28 evaluable patients...
BioCentury | Jan 13, 2017

Advancing apoptosis

A RMB500 million ($72 million) series B round will enable Ascentage Pharma Group Corp. Ltd. to generate clinical proof-of-concept data for two to three cancer candidates in three years. Future Industry Investment Fund led the...
BC Extra | Aug 14, 2015
Financial News

Ascentage Pharma raises $15.5M in series A

Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) raised $15.5 million in a series A round led by Oriza Seed Capital and YuanMing Capital. EFung Capital; BioVenture Capital; Grains Valley Venture Capital; and undisclosed investors...
Items per page:
1 - 6 of 6